Duration of viable virus shedding in SARS-CoV-2 omicron variant infection
ABSTRACT Clinical features of SARS-CoV-2 Omicron variant infection, including incubation period and transmission rates, distinguish this variant from preceding variants. However, whether the duration of shedding of viable virus differs between omicron and previous variants is not well understood. To characterize how variant and vaccination status impact shedding of viable virus, we serially sampled symptomatic outpatients newly diagnosed with COVID-19. Anterior nasal swabs were tested for viral load, sequencing, and viral culture. Time to PCR conversion was similar between individuals infected with the Delta and the Omicron variant. Time to culture conversion was also similar, with a median time to culture conversion of 6 days (interquartile range 4-8 days) in both groups. There were also no differences in time to PCR or culture conversion by vaccination status..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boucau, Julie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.03.01.22271582 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI035398442 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI035398442 | ||
| 003 | DE-627 | ||
| 005 | 20240424105311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.03.01.22271582 |2 doi | |
| 035 | |a (DE-627)XBI035398442 | ||
| 035 | |a (biorXiv)10.1101/2022.03.01.22271582 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boucau, Julie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Duration of viable virus shedding in SARS-CoV-2 omicron variant infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Clinical features of SARS-CoV-2 Omicron variant infection, including incubation period and transmission rates, distinguish this variant from preceding variants. However, whether the duration of shedding of viable virus differs between omicron and previous variants is not well understood. To characterize how variant and vaccination status impact shedding of viable virus, we serially sampled symptomatic outpatients newly diagnosed with COVID-19. Anterior nasal swabs were tested for viral load, sequencing, and viral culture. Time to PCR conversion was similar between individuals infected with the Delta and the Omicron variant. Time to culture conversion was also similar, with a median time to culture conversion of 6 days (interquartile range 4-8 days) in both groups. There were also no differences in time to PCR or culture conversion by vaccination status. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Marino, Caitlin |e verfasserin |4 aut | |
| 700 | 1 | |a Regan, James |e verfasserin |4 aut | |
| 700 | 1 | |a Uddin, Rockib |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhary, Manish C. |e verfasserin |4 aut | |
| 700 | 1 | |a Flynn, James P. |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Stuckwisch, Ashley M. |e verfasserin |4 aut | |
| 700 | 1 | |a Mathews, Josh |e verfasserin |4 aut | |
| 700 | 1 | |a Liew, May Y. |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Arshdeep |e verfasserin |4 aut | |
| 700 | 1 | |a Lipiner, Taryn |e verfasserin |4 aut | |
| 700 | 1 | |a Kittilson, Autumn |e verfasserin |4 aut | |
| 700 | 1 | |a Melberg, Meghan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yijia |e verfasserin |0 (orcid)0000-0001-5300-0571 |4 aut | |
| 700 | 1 | |a Gilbert, Rebecca F. |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Iyer, Surabhi L. |e verfasserin |4 aut | |
| 700 | 1 | |a Chamberlin, Grace C. |e verfasserin |4 aut | |
| 700 | 1 | |a Vyas, Tammy D. |e verfasserin |4 aut | |
| 700 | 1 | |a Goldberg, Marcia B. |e verfasserin |4 aut | |
| 700 | 1 | |a Vyas, Jatin M. |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jonathan Z. |e verfasserin |4 aut | |
| 700 | 1 | |a Lemieux, Jacob E. |e verfasserin |4 aut | |
| 700 | 1 | |a Siedner, Mark J. |e verfasserin |4 aut | |
| 700 | 1 | |a Barczak, Amy K. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1056/nejmc2202092 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.03.01.22271582 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||